Literature DB >> 685905

Guide to oral theophylline therapy for the treatment of chronic asthma.

L Hendeles, M Weinberger, R Wyatt.   

Abstract

Theophylline, when used appropriately, seems to be the most effective noncorticosteroid prophylactic medication for chronic asthma. Dosage, however, requires consideration of the relationship between serum concentration, efficacy, and toxicity, in addition to the variability in rates of elimination. Therapy is initiated with 16 mg/kg/day or 400 mg/day (whichever is less) in divided doses at appropriate intervals depending on the rate of absorption of the product used. If side effects are absent, the dosage is increased at three-day intervals until the age-related mean dosage necessary to produce a therapeutic level, is reached. Final dosage adjustment is generally based on a single determination of serum concentration; dosage requirements generally then remain constant for six to 12 months depending upon the child's growth rate. Dosage adjustment in this manner optimizes benefit, minimizes risk of toxic effect, and avoids excessive numbers of serum theophylline measurements.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 685905

Source DB:  PubMed          Journal:  Am J Dis Child        ISSN: 0002-922X


  14 in total

1.  Seizures from theophylline use.

Authors:  R G Dellen
Journal:  West J Med       Date:  1983-03

Review 2.  Monitoring serum theophylline levels.

Authors:  L Hendeles; M Weinberger; G Johnson
Journal:  Clin Pharmacokinet       Date:  1978 Jul-Aug       Impact factor: 6.447

3.  Control of asthma.

Authors:  J Dolovich; F E Hargreave; W M Wilson; J Greenbaum; A C Powles; M T Newhouse
Journal:  Can Med Assoc J       Date:  1982-03-15       Impact factor: 8.262

4.  Bronchodilator drugs in childhood asthma.

Authors:  A D Milner
Journal:  Arch Dis Child       Date:  1981-02       Impact factor: 3.791

5.  Diffusion and flow transfer of theophylline across the blood-brain barrier: pharmacokinetic analysis.

Authors:  M D Karol; P Veng-Pedersen; R E Brashear
Journal:  J Pharmacokinet Biopharm       Date:  1983-06

6.  Pharmacokinetics of a sustained-release theophylline formulation.

Authors:  P W Trembath; S W Boobois
Journal:  Br J Clin Pharmacol       Date:  1980-04       Impact factor: 4.335

7.  Salivary and urine theophylline levels in management of childhood asthma.

Authors:  S J Goldsworthy; M Kemp; J O Warner
Journal:  J R Soc Med       Date:  1981-06       Impact factor: 5.344

8.  Slow-release theophylline preparations.

Authors:  M Weinberger
Journal:  Arch Dis Child       Date:  1979-07       Impact factor: 3.791

Review 9.  A clinical and pharmacokinetic basis for the selection and use of slow release theophylline products.

Authors:  L Hendeles; R P Iafrate; M Weinberger
Journal:  Clin Pharmacokinet       Date:  1984 Mar-Apr       Impact factor: 6.447

10.  Theophylline pharmacokinetics following single and repeated administration of slow-release capsules.

Authors:  J Torrent; I Izquierdo; M J Barbanoj; R Obach; M Nomen; F Jane
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1988 Oct-Dec       Impact factor: 2.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.